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PURPOSE RESULTS RESULTS
We have developed a bivalent IgG antibody mimetic called 
Fab-PEG-Fab (FpF) (Fig 1) [1]. The Fc region of the IgG is 
replaced in the FpF with a flexible, hydrophilic poly(ethylene 
glycol) (PEG) scaffold. The conjugation is thought to enhance the 
stability and the PEG scaffold to reduce the propensity for 
aggregation. The potential increased stability of FpFs compared 
to IgG antibodies is being determined in an effort to develop more 
stable and useful FpF dosage forms (e.g. depots) than may be  
possible with IgGs. 
The aim of this study was to evaluate the stability of FpFs 
in storage and in a freeze-dried form in buffer only.
CONCLUSION
These preliminary results suggest that FpFs are more stable in liquid 
form and when freeze-dried without the addition of excipients (e.g. 
trehalose). The apparent increased stability of FpFs provides an 
opportunity to formulate these antibody mimetics in high concentration 
for use in tissue implantable depot forms. 
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v FpFs were prepared as described [1] using the anti-vascular 
endothelial growth factor (anti-VEGF) ranibizumab (Fabrani), 
Fabbeva and PEG-di(bis-sulfone) 1.
v Fabbeva obtained from enzymatic digestion of anti-VEGF 
bevacizumab. 
v Storage stability studies were conducted in glass vials at 4oC 
with the Fabbeva, and FpFbeva at concentration of 5 𝛍M for a 
period of 60 days.  
v Bevacizumab and Fabrani (40 𝛍M) were dialysed against PBS 
pH 7.4 before being freeze-dried to remove their formulation 
excipients. FpFrani was prepared at concentration of 40 𝛍M in 
PBS pH 7.4 buffer with no excipients. 
v Freeze-drying was conducted with primary drying at -20 0C for 
24 hours at 100μBar vacuum pressure and followed by 
secondary drying at 20 0C for 2 hours. Lyophilised bevacizumab, 
Fabrani and FpFrani were then reconstituted into water (0.3 mL) to 
study the aggregation. 
v Aggregation and light/heavy chain dissociation were studied 
using a dynamic light scattering (DLS) DynoPro plate reader II, 
gel electrophoresis SDS-PAGE analysis and size-exclusion 
chromatography (SEC). 
Figure 1. Structure of IgG and IgG mimetic (FpF).
The non-formulated FpFrani did not show any aggregation or light 
/ heavy chain dissociation after being freeze-dried  DynoPro and SEC) 
(Fig. 2 (A) and (B)). In contrast, the de-formulated bevacizumab and 
Fabrani displayed evidence of aggregation after freeze-drying (Fig. 2A-
B) Fabbeva that was freshly prepared from the proteolytic digestion of 
bevacizumab appeared as a band at 50 kDa (SDS-PAGE) with no trace 
of aggregation and a single DLS peak (Fig. 3, lane 1). Fabbeva, 
however, aggregated when it was stored in PBS buffer for 60 days at 
4oC as shown by the higher molecular weight bands in Fig. 2 (A) lane 2. 
FpFbeva did not aggregate or display any light /heavy chain dissociation 
when it was stored in the same buffer and storage conditions as Fabbeva
(5 𝛍M; Fig. 3, lanes 3-4, single DLS peak).
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(B) SEC for Fabrani and FpFrani at 40 𝛍M after freeze-drying.
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Figure 2. Stability of lyophilised anti-VEGF FpFrani,  de-formulated bevacizumab and Fabrani. Lyophilised 
powders were reconstituted in water prior to analysis by DLS (A) and SEC (B) analysis.
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Figure 3. Storage Stability of anti-VEGF FpFbeva and Fabbeva in liquid 
form in PBS over period of 60 days at 40C. 
